Dr. Madelyn Lew Changing Medical Education for Michigan Medical Students

In the Department of Pathology, Madelyn Lew, MD, goes above and beyond in medical education, solidifying her excellence in pathology and education. This year, for the Faculty and Staff Awards, she was awarded the Lifetime Achievement in Medical Education Award. Lew is the director of the program for learning innovation and career enhancement, a Clinical Professor of Pathology, and the Director of Pathology Education and Curriculum. Lew was nominated by her colleagues and trainees.

Drs. Ali-Fehmi and Mehra Named to Hour Detroit’s 2025 “Top Docs” List

Congratulations to Dr. Rouba Ali-Fehmi and Dr. Rohit Mehra for being named among Hour Detroit magazine’s “Top Docs” of 2025. Drs. Ali-Fehmi and Mehra are two of only six pathologists recognized this year out of more than 1,000 physicians across all specialties, highlighting the department’s ongoing excellence in research, education, and clinical leadership.

From Patient Mysteries to Breakthroughs: Dr. Kejian Zhang’s Lifelong Mission

The Department of Pathology is home to world-class faculty from around the world. One of these is Dr. Kejian Zhang, clinical professor and director of the molecular genetics laboratory in the Division of Genetics and Genomics. Zhang originally came to the United States to learn how to perform clinical research. “I started at the Cincinnati Children’s Hospital performing research in the Hematology Oncology department. I was there for seven or eight years before I started my fellowship in human genetics.

Dr. Kamran Mirza & Michele Mitchell on The Pathologist's Power List 2025

The Pathologist's Power List, released every year, recognizes individuals who are shaping the future of pathology and laboratory medicine. The 2025 honorees list is comprised of leading voices who challenge established ideas and advocate for reform. Among the honorees are Dr. Kamran Mirza, Godfrey D. Stobbe Professor of Pathology Education, Director of the Division of Education, and Co-Chair of the Patient and Faculty Advisory Committee, and Michele Mitchell, Patient Advocate and Co-Chair of the Patient and Faculty Advisory Committee.

FDA Approves First-Ever Drug for a Rare and Aggressive Brain Cancer

Department of Pediatrics originally published in 2023 has lead the U.S. Food and Drug Administration (FDA) to accelerate approval of the drug ONC201 now called dordaviprone for the treatment of diffuse midline glioma (DMG) with an H3 K27M mutation. A rare, aggressive brain tumor that primarily affects children and young adults. This marks the first FDA-approved therapy for this form of cancer.